French vaccine maker Valneva said Monday it has sold a $103 million priority review voucher it received from the U.S. Food and Drug Administration. Valneva received PRV certification for the tropical disease in November 2023 after developing Ixchiq, its single-dose vaccine to prevent the disease caused by the chikungunya virus, the company said.